Amgen results for Kyprolis could sideline Velcade

March 2, 2015 8:28 PM

8 0

Amgen results for Kyprolis could sideline Velcade

A phase-III study comparing Amgen's cancer drug Kyprolis (carfilzomib) with Velcade (bortezomib) favored Kyprolis, which could set the drug up to dominate the proteosome inhibitor class.

The Endeavor clinical trials showed progression-free survival among Kyprolis patients who had had between one and three previous rounds of therapy reached 18.7 months compared with the 9.4 months of progression-free survival among Velcade patients. Kyprolis is currently approved for multiple myeloma...

Also watch: 2017 NFL Draft picks: High school recruiting star rankings for first round selections

Read more

To category page

Loading...